Analyst Reco. Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Market Closed - Nasdaq Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
1.45 ^USD	-3.33%		+2.84%	-93.59%

06-18	Top Midday Decliners	MT
06-18	Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy	06-18	MT
TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy	06-18	MT
Evercore ISI Downgrades Aerovate Therapeutics to In Line From Outperform, Adjusts Price Target to $2 From $27	06-18	MT
Jefferies Downgrades Aerovate Therapeutics to Hold From Buy, Cuts Price Target to $2 From $65; Shares Plummet	06-17	MT
Wells Fargo Downgrades Aerovate Therapeutics to Equalweight From Overweight, Cuts Price Target to $2 From $35; Shares Plummet	06-17	MT
BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	06-17	MT
Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41	06-17	MT
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	04-12	MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	04-04	MT
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	03-21	MT
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	15/08/23	MT
Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating	17/05/23	MT
Guggenheim Initiates Aerovate Therapeutics at Buy With $36 Price Target	01/03/23	MT
Wedbush Raises Aerovate Therapeutics' PT to $54 From $27 on Increased Confidence in Inhaled TKIs, AV-10; Keeps Outperform Rating	12/12/22	MT
BTIG Upgrades Aerovate Therapeutics to Buy From Neutral, Price Target Is $27	06/12/22	MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at Outperform With $27 Price Target, Down From $32	19/09/22	MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at $27, Down From $32; Outperform Rating Kept	19/09/22	MT
Wedbush Lifts Price Target on Aerovate Therapeutics to $32 From $23, Keeps Outperform Rating	17/08/22	MT
BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	16/08/22	MT
BTIG Initiates Aerovate Therapeutics at Buy With $24 Price Target	11/02/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Analyst Reco.

Filters